Authors:
BRIASOULIS E
JUDSON I
PAVLIDIS N
BEALE P
GROOT Y
VEERMAN G
SCHUESSLER M
RAMMOU D
WALKER R
HANAUSKE A
Citation: E. Briasoulis et al., PHASE-I TRIAL AND PHARMACOKINETICS OF BETA-D-GLUCOSYLISOPHOSPHORAMIDEMUSTARD (D-19575) ADMINISTERED AS A 6-HOUR INFUSION EVERY 3 WEEKS - AN EORTC-ECSG STUDY, Annals of oncology, 9, 1998, pp. 616-616
Authors:
REES C
BEALE P
PLUMMER R
HIGHLEY M
CALVERT AH
JUDSON I
SMITH R
HUTCHISON M
AVERBUCH S
MAYNE K
Citation: C. Rees et al., PHASE-I TRIAL OF ZD9331 GIVEN AS A 30 MINUTE INFUSION ON DAYS 1 AND 8WITH CYCLES REPEATED EVERY 3 WEEKS, Annals of oncology, 9, 1998, pp. 628-628
Authors:
BEALE P
JUDSON I
REES C
TRIGO J
NYHART E
WOLF L
WALKER R
MOORE S
HANWELL J
Citation: P. Beale et al., PHASE-I TRIAL OF THE DIARYLSULFONYLUREA LY295501 ADMINISTERED ORALLY ONCE-DAILY FOR 5 DAYS EVERY 28 DAYS, Annals of oncology, 9, 1998, pp. 439-439
Authors:
BRIASOULIS E
JUDSON I
PAVLIDIS N
BEALE P
WANDERS J
GROOT Y
VEERMAN G
LOCHER M
SCHUESSLER M
TZAMAKOU E
RAMMOU D
WOLF L
WALKER R
HANAUSKE A
Citation: E. Briasoulis et al., A PHASE-I TRIAL OF D19575, A BETA-D-GLUCOSE-LINKED ISOPHOSPHORAMIDE MUSTARD GIVEN AS A 6-HOUR INFUSION, Annals of oncology, 9, 1998, pp. 473-473
Citation: Jm. Trigo et al., IMPACT OF PHASE-I TRIALS ON THE OUTCOME OF CANCER-PATIENTS - THE INSTITUTE-OF-CANCER-RESEARCH EXPERIENCE, Annals of oncology, 9, 1998, pp. 486-486
Authors:
REES C
BEALE P
MITCHELL F
JACKMAN A
SMITH R
MAYNE K
HUTCHISON M
JUDSON I
Citation: C. Rees et al., PHASE-I TRIAL OF ZD9331, A NON-POLYGLUTAMATABLE THYMIDYLATE SYNTHASE (TS) INHIBITOR GIVEN AS A 5 DAY CONTINUOUS-INFUSION, Annals of oncology, 9, 1998, pp. 609-609
Authors:
PLUMMER R
CALVERT AH
JUDSON I
BEALE P
REES C
GOKAL S
HIGHLEY M
LIND M
SMITH R
HUTCHISON M
MAYNE K
Citation: R. Plummer et al., PHASE-I TRIAL OF ZD9331 GIVEN AS A 30 MINUTE INFUSION ON DAYS 1 AND 8WITH CYCLES REPEATED EVERY 3 WEEKS, Annals of oncology, 9, 1998, pp. 617-617
Authors:
BEALE P
JUDSON I
HANWELL J
BERRY C
AHERNE W
HICKISH T
MARTIN P
WALKER M
Citation: P. Beale et al., METABOLISM, EXCRETION AND PHARMACOKINETICS OF A SINGLE-DOSE OF [C-14]-RALTITREXED IN CANCER-PATIENTS, Cancer chemotherapy and pharmacology, 42(1), 1998, pp. 71-76
Authors:
JUDSON I
MAUGHAN T
BEALE P
PRIMROSE J
HOSKIN P
HANWELL J
BERRY C
WALKERS M
SUTCLIFFE F
Citation: I. Judson et al., EFFECTS OF IMPAIRED RENAL-FUNCTION ON THE PHARMACOKINETICS OF RALTITREXED (TOMUDEX ZD1694), British Journal of Cancer, 78(9), 1998, pp. 1188-1193
Authors:
BEALE P
ROGERS P
HOBBS S
BOXALL F
KELLAND L
Citation: P. Beale et al., TRANSFECTION OF BAX INTO RESISTANT HUMAN OVARIAN-CARCINOMA CELL-LINESCONFERS NO SENSITIZATION TO CHEMOTHERAPEUTIC-AGENTS, British Journal of Cancer, 78, 1998, pp. 23-23
Authors:
SLEYTR UB
BAYLEY H
SARA M
BREITWIESER A
KUPCU S
MADER C
WEIGERT S
UNGER FM
MESSNER P
JAHNSCHMID B
SCHUSTER B
PUM D
DOUGLAS K
CLARK NA
MOORE JT
WINNINGHAM TA
LEVY S
FRITHSEN I
PANKOVC J
BEALE P
GILLIS HP
CHOUTOV DA
MARTIN KP
Citation: Ub. Sleytr et al., APPLICATIONS OF S-LAYERS, FEMS microbiology reviews, 20(1-2), 1997, pp. 151-175